Search research articles
Contact Us
Filters
Showing results (1-10 of 52) with videos related to
Page
of 6
Sort By:
Journal of the American Society of Nephrology : JASN
|
July 1, 2005
Asymmetric dimethylarginine and kidney disease--marker or mediator?
Patrick Vallance, James Leiper
Arteriosclerosis, Thrombosis, and Vascular Biology
|
March 31, 2012
Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?
Ben Caplin, James Leiper
Arteriosclerosis, Thrombosis, and Vascular Biology
|
April 24, 2004
Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway
Patrick Vallance, James Leiper
Nature Reviews. Drug Discovery
|
December 4, 2002
Blocking NO synthesis: how, where and why?
Patrick Vallance, James Leiper
Arteriosclerosis, Thrombosis, and Vascular Biology
|
June 24, 2006
New tricks from an old dog: nitric oxide-independent effects of dimethylarginine dimethylaminohydrolase
James Leiper, Patrick Vallance
Nature Reviews. Drug Discovery
|
April 2, 2011
The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis
James Leiper, Manasi Nandi
Methods in Enzymology
|
April 1, 2008
Rho GTPases and hypoxia in pulmonary vascular endothelial cells
Beata Wojciak-Stothard, James Leiper
Vascular Medicine (London, England)
|
February 1, 2006
Endogenous production of nitric oxide synthase inhibitors
Shelagh Anthony, James Leiper, Patrick Vallance
Vascular Medicine (London, England)
|
March 29, 2008
Over-expression of GTP-cyclohydrolase 1 feedback regulatory protein attenuates LPS and cytokine-stimulated nitric oxide production
Manasi Nandi, Peter Kelly, Patrick Vallance, et al.
European Heart Journal
|
June 5, 2026
British Heart Foundation Data Science Centre 2.0: faster, fairer cardiovascular data-driven discovery
Steffen E Petersen, Rhoswyn A Walker, James Leiper
Page
of 6
Search research articles
Search
Showing results (1-10 of 52) with videos related to
Sort By:
Page
of 6
Journal of the American Society of Nephrology : JASN
|
July 1, 2005
Asymmetric dimethylarginine and kidney disease--marker or mediator?
Patrick Vallance, James Leiper
Arteriosclerosis, Thrombosis, and Vascular Biology
|
March 31, 2012
Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?
Ben Caplin, James Leiper
Arteriosclerosis, Thrombosis, and Vascular Biology
|
April 24, 2004
Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway
Patrick Vallance, James Leiper
Nature Reviews. Drug Discovery
|
December 4, 2002
Blocking NO synthesis: how, where and why?
Patrick Vallance, James Leiper
Arteriosclerosis, Thrombosis, and Vascular Biology
|
June 24, 2006
New tricks from an old dog: nitric oxide-independent effects of dimethylarginine dimethylaminohydrolase
James Leiper, Patrick Vallance
Nature Reviews. Drug Discovery
|
April 2, 2011
The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis
James Leiper, Manasi Nandi
Methods in Enzymology
|
April 1, 2008
Rho GTPases and hypoxia in pulmonary vascular endothelial cells
Beata Wojciak-Stothard, James Leiper
Vascular Medicine (London, England)
|
February 1, 2006
Endogenous production of nitric oxide synthase inhibitors
Shelagh Anthony, James Leiper, Patrick Vallance
Vascular Medicine (London, England)
|
March 29, 2008
Over-expression of GTP-cyclohydrolase 1 feedback regulatory protein attenuates LPS and cytokine-stimulated nitric oxide production
Manasi Nandi, Peter Kelly, Patrick Vallance, et al.
European Heart Journal
|
June 5, 2026
British Heart Foundation Data Science Centre 2.0: faster, fairer cardiovascular data-driven discovery
Steffen E Petersen, Rhoswyn A Walker, James Leiper
Page
of 6